Evaluating pain management methods for minimally invasive cancer surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This research evaluates the effectiveness of three different pain management regimens during minimally invasive oncologic surgeries. Participants will be randomly assigned to receive either a combination of Laparoscopic Transversus Abdominis Plane Block (LapTAP) with Local Anesthetic, LapTAP alone, or Local Anesthetic alone. The study aims to compare these approaches to determine which provides the best postoperative pain control. Data will be collected from patients' medical records to assess outcomes and refine clinical protocols for pain management in cancer surgery.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Male and female patients age ≥ 18 - 89
2. Patients scheduled for elective (clinically indicated) hepatic, gastric, biliary, pancreatic, gynecologic, colorectal, other GI Minimally invasive oncologic surgery.
3. Patients who have provided informed consent to participate in the study.
4. Patients with an American Society of Anesthesiologists (ASA) physical status classification of I, II, or III.
5. Patients undergoing procedures anticipated to last more than 1 hour but less than 8 hours.
6. Patients able to understand and self-report pain using the designated pain Visual Analog Scale

Exclusion Criteria:

1. Patients age less than 18 or ≥ 90
2. Pre-existing hepatic dysfunction, cirrhosis
3. Patients with an ASA classification of IV or higher.
4. Patients with chronic pain disorders or on long-term opioid or analgesic therapy.
5. Patients with known contraindications to the study drugs or procedures (e.g., allergy to LA or contraindications to LapTAP).
6. Patients with cognitive impairments or psychiatric conditions that could interfere with pain assessment or understanding of informed consent.
7. Patients unable to understand the language in which consent and study-related information are provided (The study and the study-related information will be in the English Language)..
8. Patients who have undergone major surgery within the last 6 months.
9. Female patients who are pregnant.
10. Patients currently enrolled in another clinical trial that might interfere with the outcome measures of this study.

Where it's running

• AHN West Penn Hospital
  Pittsburgh, Pennsylvania, United States Recruiting

Study contacts

• Principal investigator: Casey Allen, MD — Allegheny Health Network
• Study coordinator: Casey Allen, MD
• Email: casey.allen@ahn.org
• Phone: (412) 913-6466

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• ABBV-253 in adults with advanced solid tumors

  This study tests ABBV-253 to see if it is safe, how it affects the cancer, and how the drug moves in the body for adults with advanced solid tumors.

  Recruiting at 3 sites Phase 1 AbbVie · Grand Rapids, Michigan and 2 other locations · NCT07807956

• ctDNA-guided precision care for lung, GIST, colorectal, biliary, and ovarian cancers

  This trial tests a blood test that looks for tumor DNA in patients with several cancers to help guide personalized treatment decisions.

  Recruiting Royal Marsden NHS Foundation Trust · London · NCT07673861

• Using CYTALUX (pafolacianine) with a near-infrared camera to help find cancer during surgery

  This trial will test whether a single injection of CYTALUX (pafolacianine) helps surgeons see gastrointestinal, foregut, pancreatic, hepatobiliary, esophageal, and gynecologic cancers during surgery using a special near-infrared camera.

  Recruiting Phase 2 University of Texas Southwestern Medical Center · Dallas, Texas · NCT07039526

• Testing ZM008 alone and with Pembrolizumab in patients with advanced solid tumors

  This study is testing a new treatment called ZM008, alone and with another drug called Pembrolizumab, to see if it can help patients with advanced solid tumors who have run out of other treatment options.

  Recruiting at 3 sites Phase 1 Zumutor Biologics Inc. · Boston, Massachusetts and 2 other locations · NCT06451497

• Treatment for advanced gastrointestinal cancers using MK-2870 with or without chemotherapy

  This study is testing whether a new drug called MK-2870, alone or with chemotherapy, can help people with advanced gastrointestinal cancers like colorectal, pancreatic, or biliary tract cancer feel better and improve their treatment outcomes.

  Recruiting at 30 sites Phase 1/2 Merck Sharp & Dohme LLC · Los Angeles, California and 54 other locations · NCT06428409

• Personalized self-management program to help colorectal cancer survivors adopt healthier habits

  This study will test whether a 6-week personalized self-management program helps colorectal and other gastrointestinal cancer survivors stick to healthy behavior recommendations better than a standardized program.

  Recruiting University of Southern California · Los Angeles, California and 1 other locations · NCT05984589

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.